ストックスクリーナーアプリを入手
1.22
3.17%
-0.04
アフターアワーズ：
1.21
-0.01
-0.82%
前日終値:
$1.26
開ける：
$1.21
24時間の取引高:
1.79M
Relative Volume:
0.84
時価総額：
$250.10M
収益：
$12.87M
当期純損益:
$-114.34M
株価収益率:
-1.4111
EPS:
-0.8646
ネットキャッシュフロー:
$-79.23M
1週間 パフォーマンス:
-36.79%
1か月 パフォーマンス:
-25.15%
6か月 パフォーマンス:
-39.30%
1年 パフォーマンス:
-54.48%
1日の値動き範囲:
$1.19
$1.24
1週間の範囲:
$1.17
$1.79
52週間の値動き範囲:
$1.17
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
名前
Taysha Gene Therapies Inc
セクター
電話
(214) 612-0000
住所
3000 PEGASUS PARK DRIVE, DALLAS
TSHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
1.22 | 250.10M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-04-09 | 開始されました | Piper Sandler | Overweight |
| 2023-02-01 | ダウングレード | Jefferies | Buy → Hold |
| 2023-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-03-09 | 開始されました | Robert W. Baird | Outperform |
| 2022-03-01 | 開始されました | Wells Fargo | Overweight |
| 2022-02-18 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-16 | 開始されました | Guggenheim | Buy |
| 2021-07-16 | 開始されました | Needham | Buy |
| 2021-06-24 | 開始されました | Truist | Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-06-09 | 開始されました | Wedbush | Outperform |
| 2021-06-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 再開されました | Jefferies | Buy |
| 2021-02-24 | 開始されました | William Blair | Outperform |
| 2021-01-05 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-19 | 開始されました | Goldman | Buy |
| 2020-10-19 | 開始されました | Jefferies | Buy |
| 2020-10-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Taysha Gene Therapies Inc (TSHA) 最新ニュース
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Expands Team: 822,000 Stock Options Awarded in Strategic Growth Move - Stock Titan
At $1.32 Price, Taysha Gene Therapies Inc (TSHA) Is Sitting And Waiting - stocksregister.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com India
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia
Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World
Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan
TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks
Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Taysha Gene Therapies Reports 2024 Financial Results - TipRanks
Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Taysha Gene Therapies reports FY24 EPS (36c) vs (96c) last year - TipRanks
Taysha Gene Therapies Inc Reports Full Year 2024 EPS of -$0.36 a - GuruFocus.com
Earnings call transcript: Taysha Gene's Q4 2024 reports narrower loss, stock dips - Investing.com
Earnings call transcript: Taysha Gene’s Q4 2024 reports narrower loss, stock dips - Investing.com India
Taysha Gene Therapies, Inc. SEC 10-K Report - TradingView
Can Taysha's Gene Therapy for Rett Syndrome Deliver? Key Safety Milestone Reached as Cash Extends to 2026 - StockTitan
Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World
Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times
Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Taysha Gene Therapies Inc (TSHA) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):